Dr. Reddy’s Laboratories
- Company typePublic
- Founded1984
- HeadquartersHyderabad, India
- Headcount5,001–10,000
- GTM typeB2B
- OfferingHardware or Manufacturing
Dr. Reddy’s Laboratories firmographics
Firmographics- Name
- Dr. Reddy’s Laboratories
- Legal name
- Dr. Reddy's Laboratories, Ltd.
- Website
- https://drreddys.com
- Company type
- Public
- Founded year
- 1984
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Ownership category
- akta.pro rank
Dr. Reddy’s Laboratories industry classification
Industry- Product category
- Generic Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)
- akta.pro secondary industries
- Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)
Keywords
Where Dr. Reddy’s Laboratories is headquartered
LocationHeadquarters
- HQ city
- Hyderabad
- HQ country
- India
- HQ region
- Asia
Offices4 records
Markets served
Dr. Reddy’s Laboratories business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Supply Chain, Personnel, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Generics (Branded, Unbranded, Biosimilars): Core business segment delivering advanced medicines at affordable prices across major therapeutic areas including oncology, gastroenterology, and dermatology. Revenue declined due to loss of Revlimid exclusivity but remains the largest revenue driver.
- API & Services: Development and manufacturing of high-quality APIs for pharmaceutical companies globally. Offers end-to-end pharmaceutical services including CDMO through Aurigene subsidiary. Supplies APIs to 80+ countries with 250+ products.
- Innovative Medicines: Advancing therapies that address unmet medical needs through science and technology, including Toripalimab (immuno-oncology), Lenacapavir (HIV), and CAR-T cell therapy through Aurigene Oncology.
- Consumer Health: Broad portfolio including OTC products and health solutions supporting everyday well-being.
- XACDURO Distribution Agreement: Exclusive distribution and licensing agreement with Innoviva Specialty Therapeutics for antibiotic XACDURO covering South and Central America, Caribbean, Russia, and CIS countries.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Obeda Oral Semaglutide - Tiered pricing by dosage strength |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels5 records
Dr. Reddy’s Laboratories product offering
Product offeringCore offering
Dr. Reddy's Laboratories is an integrated pharmaceutical company that develops, manufactures, and commercializes affordable generic medicines, biosimilars, Active Pharmaceutical Ingredients (APIs), innovative therapies, and consumer health products. It supplies 250+ APIs to 80+ countries and operates 8 USFDA-inspected manufacturing sites, with notable launches including Bosutinib Tablets 400mg in the US, Obeda oral semaglutide in India, and generic semaglutide injection in Canada.
Product overview
Dr. Reddy's Laboratories operates as a diversified pharmaceutical company organized across four main segments: Generics (branded, unbranded, and biosimilars), API & Services (development, manufacturing, and research support), Innovative Medicines, and Consumer Health solutions. The company also operates through subsidiaries including Aurigene Pharmaceutical Services (CRDMO services) and Aurigene Oncology (cancer treatments). Key products include biosimilar oncology treatments (Bevacizumab, Rituximab), innovative immunotherapies (Toripalimab), HIV treatments (Lenacapavir), and diabetes therapies (Obeda semaglutide). The company offers over 250 active pharmaceutical ingredients through its API Solutions business and serves markets in 80+ countries. Recent launches include Bosutinib Tablets 400mg (generic leukemia treatment) and Obeda oral semaglutide (diabetes). The company also provides digital patient support programs through platforms like Alivius (cancer patient tracking), Mintop Daily (hair loss support), and Vega Club (IBD management).
Differentiator
Problem solved
Functional benefit
Brands
- Obeda: Oral semaglutide biosimilar brand for Type 2 diabetes
- Aurigene
- Aurigene.AI
- XCEED
- Dr. Reddy's Direct
- Dr. Reddy's API
Products and services
- Generic Medicines Portfolio Branded, unbranded, and biosimilar generic medicines delivered across major therapeutic areas including oncology, gastroenterology, and dermatology, sold to distributors, healthcare providers, and patients across 80+ countries.
- Active Pharmaceutical Ingredients (APIs) Manufacturing and supply of 250+ high-quality, affordable Active Pharmaceutical Ingredients supplied to generic formulations manufacturers across 80+ countries, produced at 8 USFDA-inspected manufacturing sites.
- Innovative Medicines Novel therapies addressing unmet medical needs including immuno-oncology, HIV, and rare disease treatments, developed through internal R&D and partnerships with innovators like Gilead Sciences and Alvotech.
- Consumer Health Products Broad portfolio of OTC products and health solutions supporting everyday well-being including dermatology and trichology offerings such as Mintop Daily for hair loss support.
- Toripalimab The first immunotherapy approved by major global regulators for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC); introduces immuno-oncology as a first-line treatment for RM-NPC in combination with chemotherapy in India.
- Bevacizumab Biosimilar First biosimilar of Bevacizumab approved and launched in the UK; treatment for colorectal, lung, brain, kidney, cervical, and ovarian cancers that works by blocking VEGF protein to slow cancer growth and spread.
- Lenacapavir Long-acting, USFDA-approved treatment for HIV-1 infection; Dr. Reddy's partnership with Gilead Sciences aims to manufacture and commercialize across 120 countries.
- Obeda (Oral Semaglutide) Oral semaglutide biosimilar for Type 2 diabetes management launched in India, available in 3mg (Rs 99), 7mg (Rs 135), and 14mg (Rs 225) tablet strengths; approved by CDSCO following Phase III clinical study on 288 patients demonstrating non-inferior efficacy.
- Bosutinib Tablets 400mg First generic version of Pfizer's Bosulif for treatment of Philadelphia chromosome-positive chronic myeloid leukemia; first-to-market launch with 180-day generic exclusivity in the US market, developed in collaboration with MSN Laboratories.
- Generic Semaglutide Injection Generic semaglutide injection for Type 2 diabetes supplied as a sterile solution in pre-filled pens available in 2mg/pen and 4mg/pen strengths; Canada became the first G7 country to grant market authorization following Health Canada's Notice of Compliance on April 28, 2026.
- CAR T-Cell Therapy Novel therapeutic solution for patients with relapsed/refractory Multiple Myeloma (RRMM), a cancer of plasma cells; developed by Aurigene Oncology subsidiary with Phase 1 study results announced.
- Aurigene Pharmaceutical Services (CRDMO) Contract Research, Development and Manufacturing Organization offering integrated services across drug discovery, APIs, and finished dosage forms for small and large molecules from lab to market, powered by the Aurigene.AI drug discovery platform.
Quantifiable outcome
- Over 1.5 billion patient lives targeted by 2030
- +2 more outcomes
Companies that use Dr. Reddy’s Laboratories
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
Dr. Reddy’s Laboratories technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Dr. Reddy’s Laboratories partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core, minor and flagship.
- Innoviva Specialty TherapeuticscoreExclusive distribution and licensing agreement for XACDURO, an FDA-approved antibiotic for hospital-acquired and ventilator-associated bacterial pneumonia, covering South and Central America, Caribbean, Russia, and CIS countries. Dr. Reddy's handles development, regulatory approval, and commercialization.
- AlvotechcoreCollaboration to expand access to essential cancer therapies approved for more than 40 types of cancer, strengthening oncology care and supporting patients with high-burden diseases worldwide. Partnership involves biosimilar development including pembrolizumab.
- Nimbus Health GmbHminorAcquisition agreement for German medical cannabis firm Nimbus Health GmbH, a pioneer in Germany's medical cannabis sector valued at approximately €122 million.
- Gates FoundationflagshipWorking to develop an injectable contraceptive for low and middle income countries, advancing women's health, improving family planning options, and reducing health inequities.
- SanoficorePartnering to distribute pediatric and adult vaccines in India, expanding immunization coverage, and strengthening disease prevention.
- MSN LaboratoriescoreCollaboration for Bosutinib Tablets 400mg development and manufacturing. MSN handled development and manufacturing while Dr. Reddy's holds exclusive US marketing rights, securing 180-day first-to-file generic exclusivity.
- Aurigene Pharmaceutical ServicescoreWholly-owned subsidiary of Dr. Reddy's formed in 2020 by consolidating service businesses. Offers integrated CRO and CDMO services for small and large molecules from lab to market, with AI-powered drug discovery platform.
- Aurigene OncologycoreSubsidiary developing innovative treatments to improve lives of people with cancer and inflammatory diseases, including CAR-T cell therapy for relapsed/refractory Multiple Myeloma.
- Industrial Promotion Services (IPS)minorStrategic collaboration to support the East African Combined Pharmaceutical Center (EACPC) in Kenya, supporting pharmaceutical manufacturing localization in Africa.
- Mankind PharmaminorJoint discussion on podcast WTF with Nikhil Kamath regarding India's pharmaceutical industry evolution and growth from generics to innovation-led growth.
Scale indicators9 records
Recent moves7 records
Expansion highlights6 records
Dr. Reddy’s Laboratories competitors and assessment
Company assessmentDirect peers
- Cipla: Indian pharma major with overlapping generics, API, and respiratory/oncology portfolios and similar emerging-market distribution depth. A close competitor across Africa, India, and the US generics market.
- Biocon: Indian biopharmaceutical peer with leading biosimilars (Trastuzumab, Bevacizumab, Insulin Glargine) and a CDMO arm (Syngene). Highly comparable to Dr. Reddy's on biosimilars strategy and Aurigene-style CRDMO ambitions.
- Sun Pharmaceutical Industries: Largest Indian pharmaceutical company with comparable generics, API, and specialty franchises serving the US, India, and emerging markets. Directly competes in generic oncology, dermatology, and complex generics where Dr. Reddy's is also active.
- Aurobindo Pharma: Direct competitor in US generics, APIs, and biosimilars with comparable manufacturing scale and USFDA-inspected facilities. Closely comparable on injectable generics and emerging-market expansion strategies.
- Zydus Lifesciences: Indian integrated pharma with generics, APIs, biologics, and consumer health businesses. Overlaps heavily with Dr. Reddy's biosimilar pipeline (including their own Bevacizumab) and US generics franchise.
- Glenmark Pharmaceuticals: Indian peer with parallel generics, API, and specialty branded businesses and a growing complex generics and biosimilars pipeline. Comparable in therapeutic-area focus (dermatology, oncology, respiratory) and emerging-market footprint.
- Lupin: Indian peer with parallel generics, API, and biosimilars businesses focused on the US, India, and emerging markets. Particularly comparable in complex generics and specialty therapy areas like oncology and respiratory.
Broad incumbents
- Sandoz (Novartis): Global generics and biosimilars leader spun out from Novartis. Direct overlap with Dr. Reddy's biosimilars franchise (Bevacizumab, Rituximab, etc.) and broad geographic reach across the US and Europe.
- Viatris (formerly Mylan): Global pharma major formed from the Mylan-Upjohn combination with deep generics, biosimilars, and branded specialty portfolios. Competes head-to-head with Dr. Reddy's in US generics and emerging markets.
- Teva Pharmaceutical Industries: Largest global generics player with deep US, EU, and emerging-market footprint plus specialty and biosimilars. A broader incumbent offering overlapping capabilities including complex generics and biosimilars that compete with Dr. Reddy's portfolio.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat6 records
Key risks5 records
Key highlights6 records
Customer concentration
Dr. Reddy’s Laboratories social profiles
Digital presenceDr. Reddy’s Laboratories financial estimates
Financial estimateRevenue estimate
Valuation estimate
Dr. Reddy’s Laboratories leadership team
Management profileNumber of profiles
Profiles10 records
Dr. Reddy’s Laboratories subsidiaries and ownership
Company hierarchySubsidiaries4 records
Dr. Reddy’s Laboratories funding detail
Funding detailFunding overview
Funding rounds3 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Dr. Reddy’s Laboratories M&A and investment
M&A and investmentM&A6 records
Investments4 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Dr. Reddy’s Laboratories
What does Dr. Reddy’s Laboratories do?
Dr. Reddy's Laboratories is an integrated pharmaceutical company that develops, manufactures, and commercializes affordable generic medicines, biosimilars, Active Pharmaceutical Ingredients (APIs), innovative therapies, and consumer health products. It supplies 250+ APIs to 80+ countries and operates 8 USFDA-inspected manufacturing sites, with notable launches including Bosutinib Tablets 400mg in the US, Obeda oral semaglutide in India, and generic semaglutide injection in Canada.
Is Dr. Reddy’s Laboratories a public or private company?
Dr. Reddy’s Laboratories is a public company. It is classified as public and is currently operating.
When was Dr. Reddy’s Laboratories founded?
Dr. Reddy’s Laboratories was founded in 1984. It employs 5,001 to 10,000 people.
Where is Dr. Reddy’s Laboratories based?
Dr. Reddy’s Laboratories is headquartered in Hyderabad, India, in the Asia region.
How does Dr. Reddy’s Laboratories make money?
Five revenue lines are on record. Generics (Branded, Unbranded, Biosimilars) is the primary driver. The others are API & Services, innovative Medicines, consumer Health and XACDURO Distribution Agreement.
Who are Dr. Reddy’s Laboratories's main competitors?
Direct peers on record are Cipla, Biocon, Sun Pharmaceutical Industries, Aurobindo Pharma, Zydus Lifesciences, Glenmark Pharmaceuticals and Lupin. Broad incumbents are Sandoz (Novartis), Viatris (formerly Mylan) and Teva Pharmaceutical Industries.
Does Dr. Reddy’s Laboratories have an API?
No public API is recorded for Dr. Reddy’s Laboratories.
What industry is Dr. Reddy’s Laboratories in?
Dr. Reddy’s Laboratories's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAH, Generic Finished Dosage Form (FDF) Manufacturing, with a secondary code of HLAGAHAM, Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC). Its NAICS code is 325412 and its SIC code is 2836.